Filtered By:
Source: Oncology Reports
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non ‑small cell lung cancer cells
Oncol Rep. 2021 Jun;45(6):102. doi: 10.3892/or.2021.8053. Epub 2021 Apr 28.ABSTRACTOverexpression of ETS‑homologous factor (EHF) in non‑small cell lung cancer (NSCLC) is associated with poor patient prognosis. To explore the mechanism of the effect of EHF in NSCLC, EHF expression was examined in NSCLC and its role in cell proliferation, invasion, cell cycle, and apoptosis of NSCLC cells was evaluated by overexpressing EHF and/or knocking down EHF expression in NSCLC cells in vitro and in cancer cell grafted mice in vivo. The results revealed that the knockdown of EHF expression in NSCLC with siRNA significantly inhibit...
Source: Oncology Reports - April 28, 2021 Category: Cancer & Oncology Authors: Lei Gao Tian Yang Shuo Zhang Yiqian Liang Puyu Shi Hui Ren Peng Hou Mingwei Chen Source Type: research

RAD52 motif ‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation.
This study aimed to investigate the role of RDM1 in the progression of non‑small cell lung cancer (NSCLC). We found elevated RDM1 mRNA and protein expression in NSCLC tissues and cell lines compared to levels in normal lung cells. RDM1 protein expression in lung cancer tissues was found to correlate with tumor size, histological differentiation, lymph node metastasis and tumor‑node‑metastasis (TNM) stage. Knockdown of the RDM1 gene with siRNA significantly reduced the cellular proliferation rate and increased apoptosis in the human NSCLC cell line, NCI‑H1299. Compared to wild‑type NCI‑H1299 cells, RDM1 knockdow...
Source: Oncology Reports - June 1, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
In conclusion, ERβ1 was activated in EGFR-TKI secondary resistance. The downregulation of ERβ1 sensitized the cells to EGFR-TKIs. ERβ1 may be a key molecule in EGFR-TKI therapy. In addition, anti-ERβ1 treatment may reverse TKI resistance. PMID: 29328407 [PubMed - as supplied by publisher]
Source: Oncology Reports - January 14, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Authors: Li Y, Hu T, Chen T, Yang T, Ren H, Chen M Abstract A major common medical treatment for lung carcinoma is cisplatin (DDP)-based therapy. However, the development or existence of chemoresistance frequently blocks its effectiveness. Currently, autophagy is recognised as a potential anticancer strategy, although there is controversy over its role in the development of cancer. In lung carcinoma, no studies of autophagy induced by FTY720, a sphingosine 1-phosphate analog and a novel immunosuppressant drug, have been published, while apoptosis has been shown to be induced by FTY720 in several cancer cell lines. ...
Source: Oncology Reports - December 6, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.
Authors: Yang L, Zha TQ, He X, Chen L, Zhu Q, Wu WB, Nie FQ, Wang Q, Zang CS, Zhang ML, He J, Li W, Jiang W, Lu KH Abstract Pulmonary carcinoma-associated proteins have emerged as crucial players in governing fundamental biological processes such as cell proliferation, apoptosis and metastasis in human cancers. Placenta-specific protein 1 (PLAC1) is a cancer-related protein, which is activated and upregulated in a variety of malignant tissues, including prostate cancer, gastric adenocarcinoma, colorectal, epithelial ovarian and breast cancer. However, its biological role and clinical significance in non-small cell...
Source: Oncology Reports - November 16, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression.
Authors: Li GJ, Zhao GQ, Yang JP, Zhou YC, Yang KY, Lei YJ, Huang YC Abstract The aim of this study was to investigate the function of miR-1244 in cisplatin-treated non-small cell lung cancer (NSCLC). The results of quantitative PCR analysis revealed that the expression levels of miR-1244 in cisplatin‑treated A549 and NCI-H522 human lung cancer cell lines were lower than those in untreated A549 and NCI-H522 cells. Similarly, the expression level of miR-1244 in NSCLC tissue samples from cisplatin-treated patients was also lower than that in non-cisplatin-treated NSCLC patients. Notably, the overall survival times ...
Source: Oncology Reports - May 13, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Authors: Liu L, Xiao L, Liang X, Chen L, Cheng L, Zhang L, Wu X, Xu Q, Ma C Abstract Tripartite motif containing 28 (TRIM28) is a universal corepressor for Kruppel‑associated box zinc finger proteins. In our previous study, it was shown that expression of TRIM28 is upregulated in non‑small cell lung cancer (NSCLC) cell lines and tissues. Here, we demonstrated that the stable silencing of TRIM28 expression by a specific siRNA lentivirus vector increased the sensitivity of NSCLC cells to chemotherapeutic agent etoposide. Combination of TRIM28 siRNA and etoposide significantly inhibited the growth and proliferatio...
Source: Oncology Reports - May 13, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines.
Authors: Yan J, Ma C, Gao Y Abstract PFN2 is an invasion promoter in several cancers including lung cancer. However, the probable effects and underlying mechanisms of PFN2 in tumor cell epithelial-mesenchymal-transition (EMT) of non-small cell lung cancer (NSCLC) remain poorly understood. The protein and mRNA levels of PFN2 in human bronchial epithelial cell line 16HBE and three NSCLC cell lines A549, NCI-H520 and 95D were assessed. The gain-of-function (overexpression) and loss‑of-function (siRNA) experiments of PFN2 were performed in 95D cells. A dual-luciferase reporter assay, western blotting and real-time ...
Source: Oncology Reports - April 14, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Inhibition of CCR7 promotes NF- κB-dependent apoptosis and suppresses epithelial-mesenchymal transition in non-small cell lung cancer.
In conclusion, upregulation of CCR7 promoted cell proliferation and inflammation in A549 cells. In conclusion, inhibition of CCR7 via siRNA treatment promoted cell apoptosis and suppressed the inflammatory response and TGF-β1‑induced EMT, which may be associated with NF-κB signaling. PMID: 28339080 [PubMed - as supplied by publisher]
Source: Oncology Reports - March 27, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research